A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

Sara Gagno, Mario Rosario D'Andrea, Mauro Mansutti, Chiara Zanusso, Fabio Puglisi, Eva Dreussi, Marcella Montico, Paola Biason, Erika Cecchin, Donatella Iacono, Stefania Russo, Marika Cinausero, Silvana Saracchini, Giampietro Gasparini, Donata Sartori, Mario Bari, Elena Collovà, Rosa Meo, Ghassan Merkabaoui, Ilaria SpagnolettiArianna Pellegrino, Lorenzo Gianni, Paolo Sandri, Elisabetta Cretella, Emanuela Vattemi, Andrea Rocca, Patrizia Serra, Maria Agnese Fabbri, Giovanni Benedetti, Laura Foghini, Michele Medici, Umberto Basso, Vito Amoroso, Ferdinando Riccardi, Anna Maria Baldelli, Mario Clerico, Salvatore Bonura, Chiara Saggia, Federico Innocenti, Giuseppe Toffoli

Research output: Contribution to journalArticle

Abstract

Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a prospective study to investigate whether constitutive genetic background might affect response to therapy. In a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5–polymorphism-based genetic score could be used to identify patients with different risks of progression and death.

Original languageEnglish
JournalClinical Breast Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2018

    Fingerprint

Keywords

  • Advanced breast cancer
  • Aromatase inhibitor
  • Hormone therapy
  • Polymorphisms
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gagno, S., D'Andrea, M. R., Mansutti, M., Zanusso, C., Puglisi, F., Dreussi, E., Montico, M., Biason, P., Cecchin, E., Iacono, D., Russo, S., Cinausero, M., Saracchini, S., Gasparini, G., Sartori, D., Bari, M., Collovà, E., Meo, R., Merkabaoui, G., ... Toffoli, G. (Accepted/In press). A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2018.11.009